Trends in buprenorphine treatment disparities during the COVID pandemic in Massachusetts

Sarah E. Wakemana Department of Medicine, Massachusetts General Hospital, Boston, MA, USA;b Harvard Medical School, Boston, MA, USA;c Mass General Brigham, Office of the Chief Medical Officer, Boston, MA, USACorrespondence[email protected]

, MD,

Eugene Lamberta Department of Medicine, Massachusetts General Hospital, Boston, MA, USA;b Harvard Medical School, Boston, MA, USA

, MD,

Sunny Kunga Department of Medicine, Massachusetts General Hospital, Boston, MA, USA;b Harvard Medical School, Boston, MA, USA

, MD,

Nicholas M. Brisbond Mass General Brigham, Enterprise Analytics, Boston, MA, USA

, PhD, LMHC,

Aleta D. Carrollc Mass General Brigham, Office of the Chief Medical Officer, Boston, MA, USA

, LMHC, MBA,

Thu-Trang Hickmanc Mass General Brigham, Office of the Chief Medical Officer, Boston, MA, USA

, MPH, PMP,

Charles Covaheyd Mass General Brigham, Enterprise Analytics, Boston, MA, USA

, BS,

Thomas D. Sequistb Harvard Medical School, Boston, MA, USA;c Mass General Brigham, Office of the Chief Medical Officer, Boston, MA, USA;e Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA

, MD, MPH &

Scott G. Weinerb Harvard Medical School, Boston, MA, USA;f Department of Emergency Medicine, Brigham and Women’s Hospital, Boston, MA, USA

, MD show all

Trends in buprenorphine treatment disparities during the COVID pandemic in Massachusetts

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Trends in buprenorphine treatment disparities during the COVID pandemic in Massachusetts

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date